The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma
Authors:
- G.J. OssenkoppeleGOG.J. Ossenkoppele
- A.A.P.M. van RietARA.A.P.M. van Riet
- F.F.H. RuttenFRF.F.H. Rutten
- 1 January 1994
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 30 (4) , 457-459
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) as an Adjunct to Autologous Hemopoietic Stem Cell Transplantation for LymphomaAnnals of Internal Medicine, 1992
- High-risk multiple myeloma treated with high-dose melphalan.Journal of Clinical Oncology, 1992
- High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myelomaBlood, 1990
- Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factorBlood, 1989
- High-dose therapy and autologous peripheral blood stem cell transplantation for patients with lymphomaBlood, 1989
- Multiple myeloma treated with high dose intravenous melphalanBritish Journal of Haematology, 1987